UPDATE: Piper Jaffray Starts Moderna (MRNA) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $222.76 +4.01%
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
(Updated - January 2, 2019 3:30 AM EST)
(updated to correct company name)
Piper Jaffray analyst Edward Tenthoff initiates coverage on Moderna (NASDAQ: MRNA) with a Overweight rating and a price target of $24.00.
For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.
Shares of Moderna closed at $15.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- William Blair Downgrades Moderna (MRNA) to Market Perform
- Moderna shares slip as William Blair cuts rating on valuation after rally
- Northland Starts Digital Turbine (APPS) at Outperform, 'Proven Turnaround'
Create E-mail Alert Related Categories
New CoverageRelated Entities
Piper Jaffray, Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
